Novavax, Inc.
https://novavax.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novavax, Inc.
Russia-Ukraine War Likely To Claim Sputnik V Partners As Casualty
In light of the Russia-Ukraine conflict, Scrip looks at data to gauge if manufacturing partners for COVID-19 vaccine Sputnik V or Light, in India, China and Korea could be left holding unsold inventory earmarked for exports
Finance Watch: Bausch + Lomb Completes Split From Bausch Health Via IPO
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.
Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars
Biocon is progressing trials for biosimilar rivals to Amgen’s Prolia/Xgeva (denosumab) and J&J’s Stelara (ustekinumab), even as it gears for other large opportunities coming its way via the Viatris deal including for blockbusters Humira and Eylea.
2021 Global Biopharma R&D Productivity And Growth Ranking
A turbulent 2021: we are now in our eighth year of reviewing R&D productivity and corporate growth of the top 30 biopharma companies. While 2021 was dominated by the COVID-19 pandemic, biopharma as a whole had a good but not great year.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Vaccines
-
Biotechnology
- Liposomes
- Other Names / Subsidiaries
-
- CPL Biologicals Pvt. Ltd. (Joint Venture with Cadila)
- Isconova AB
- Novavax AB